Roger Smith joined Signant Health as Chief Executive Officer to guide the company during an exciting time of evolution and growth. Roger is focused on realizing the company’s immense unlocked value by leading customers to aggressive adoption of eCOA, IRT, and Endpoint Solutions individually, as a platform to future direct-to-patient trial conduct. His vision is for Signant to lead the industry through product roadmap priorities, customer service excellence, commercial expansion, and most importantly, coming together as one culture around these principles. Roger joins Signant from PPD, where he was Senior Vice President and General Manager of Accelerated Enrollment Solutions (AES), which offers biopharmaceutical sponsors and contract research organizations best-in-class clinical trial site conduct and patient access solutions. In his role, he was responsible for AES’s strategic direction and financial growth as its chief executive, and played a pivotal role working closely with research sites and pharmaceutical organizations to solve patient recruitment challenges by utilizing digital technology and data science. Prior to joining PPD in 2013 through its acquisition of Acurian, Mr. Smith held a number of senior management positions for Acurian, Kozmo.com and Sony Corporation. Roger brings decades of experience to the company and has a proven record of taking customer-centric technology and solutions companies like Signant Health to the next level by expanding the market for their services.
Partnering with you to deliver life-changing insights.
Chief Executive OfficerRead Bio Read Bio
John Hubbard, PhD, FCP
ChairmanRead Bio Read Bio
John brings more than 30 years of leadership experience in the biopharmaceutical industry to guide Signant Health on its mission to transform the clinical trial process by providing simple, intuitive technologies that accelerate the clinical trial process, improve clinical data quality and enhance the lives of patients around the world.
Most recently, he was President and CEO of Bioclinica, a leading provider of medical imaging and clinical technologies. Prior to Bioclinica, he was Senior Vice President and Worldwide Head of Development Operations at Pfizer. He was responsible for global drug development of more than 450 clinical trials. Before joining Pfizer, he was Group President of ICON plc’s Global Clinical Research Division and also held executive positions at Parexel International Corporation and Sanofi Pharmaceuticals (formerly Hoechst Marion Roussel).
John was a founding member of the Board of Directors of TransCelerate Biopharma, Inc., is an Executive Committee Member Emeritus on the Clinical Trials Transformation Initiative (CTTI). He is on the board of Agile Therapeutics (NASDAQ: AGRX), Life Sciences Pennsylvania, and was former Chairman of the Board of the Association of Clinical Research Organizations (ACRO). As part of his role as a Healthcare Strategic Advisory Board Member to Genstar Capital, John advises the firm on healthcare investments and serves as a board member on portfolio companies (Signant Health and Advara). He was recognized by Pharma Voice as one of the 100 Most Inspirational People of 2016.
John’s Ph.D., is in cardiovascular physiology and he is a Fellow in the American College of Clinical Pharmacology. His hobby is martial arts and holds a 4th Degree Black Belt and is a Master Instructor in Kung Jung Mu Sul. John and his wife have been married 40 years, enjoy traveling globally and reside in Doylestown, Pennsylvania.
Chief Commercial OfficerRead Bio Read Bio
Ian Jennings leads the commercial organization at Signant Health, with primary responsibility for Business Development and Marketing. Ian has 30 years of experience in the life sciences industry, with 20 years in commercial leadership roles at ClinPhone, Parexel Informatics, Exco InTouch and ERT. Ian is an advocate for the patient experience in clinical and healthcare technology, helping Signant Health evolve its unique solution portfolio to add greater value to customers and to all participants in the clinical research and development process. Ian holds a Bachelor of Science (Honors) in Applied Chemistry from Sheffield Hallam University.
Chief Marketing OfficerRead Bio Read Bio
Scott Connor joined Signant Health as Chief Marketing Officer, bringing over 30 years of marketing experience in the life sciences and technology sectors. He is responsible for positioning Signant as the leading provider of evidence generation and digital enablement of clinical trial conduct. Scott joins Signant from PPD, where he was Vice President Corporate Marketing & Strategy of Accelerated Enrollment Solutions (AES), which offers biopharmaceutical sponsors and contract research organizations best-in-class clinical trial site conduct and patient access solutions. Prior to joining PPD in 2013 through its acquisition of Acurian, Mr. Connor held marketing positions at Liquent, the leading provider of regulatory submission software and services for the biopharmaceutical industry (now a Parexel subsidiary); and SCT (now Ellucian), a developer of administrative software and outsourcing services to the higher education, local government, public utility, and process manufacturing industries. Scott graduated summa cum laude from the S.I. Newhouse School of Public Communications at Syracuse University with a B.S. in Advertising and English.
Chief Financial OfficerRead Bio Read Bio
Mitch Blumenfeld oversees Finance, Quality and all Legal and Regulatory Affairs. He joined from PCI Pharma Services, the world’s largest provider of outsourced pharmaceutical packaging and related services where he was responsible for all financial management for 18 facilities across North America, Europe and Australia. He led PCI’s finance functions during a period of rapid growth, including a ten-fold increase in EBITDA and the successful completion of five acquisitions in the US, UK, Ireland and Australia. Prior to his time with PCI, Mitch worked for AmerisourceBergen as the Senior Vice President and CFO of the Drug Corporation and led the integration and finance functions for World Courier, the world leader in global cold chain and clinical trial logistics with offices in over 140 countries. Mitch started work with GE, having a career spanning 15 years and roles in the US and Europe with the Appliances, Lighting, Information Services and Water Technology businesses as well as five years in the Corporate Audit Staff. He is a graduate of GE’s Edison Engineering Program and Advanced Courses in Engineering. Mitch holds a Bachelor of Science in Computer Science Engineering from Bucknell University and a Master of Science in Computer Science & Applications from Virginia Tech.
Chief Technology OfficerRead Bio Read Bio
Lawrence Miller is the Chief Technology Officer for Signant Health. His career has been focused on leading and scaling commercial, global technology organizations. Lawrence started as a quantitative analytics developer at JP Morgan Chase, eventually leading the development for one of the firm’s electronic trading platforms. In 2004 he joined BlackRock, where he was a Managing Director, overseeing the Development Services team for Aladdin, BlackRock’s asset management platform and the core of its successful SaaS business. While at BlackRock, Lawrence was involved in the formation of Symphony Communication Services and served as a Board Observer prior to joining the startup. At Symphony, Lawrence was Chief Security Officer, overseeing the firm’s security program, managing platform operations, and leading the firm’s regulatory and government affairs. Lawrence also served on the Commodity Futures Trading Commission’s TAC Cybersecurity Subcommittee, the Board of the FINOS FinTech Open Source Foundation, and currently serves on the University of Chicago’s Institute for Molecular Engineering Council. Lawrence holds an MS in Computer Science from The George Washington University, and a BA in Physics from the University of Chicago.
Chief Compliance and Security OfficerRead Bio Read Bio
Paul Drake, PhD, leads the compliance and security organization, responsible for quality management, information security, physical security and regulatory compliance. Paul is also appointed as Signant Health’s Data Protection Officer (DPO). He has 30 years of experience in security, quality management and data privacy, with more than 20 years in senior executive roles, most of which he has spent in the pharmaceutical industry. He also has extensive experience in complex integration work completed at major pharmaceutical companies, building IT organizations, complex technology infrastructure and change management. Paul holds a PhD in Critical Social Theory and Information Security from the University of Hull, an MSc in Supervisory Management from Anglia Ruskin University, Cambridge, and is a Master Black Belt in Lean Six Sigma.
Chief People OfficerRead Bio Read Bio
Susie Robinson oversees human resources for over 1500 employees worldwide where she is focused on executing contemporary people strategies that will accelerate innovation, scale a powerful business and remain focused on expert service for customers. With more than 15 years as a Chief Human Resources Officer and 20+ years as an HR practitioner and advisor, she is a decisive, energetic, results-driven business leader with an eye for talent and a skill for transforming organizations. She has led HR, communications, operational and technical teams of 5 to 120 members in multi-divisional, multi-cultural operations with workforces from 700-6K+ in The Americas, Europe, and Asia. Ms. Robinson holds a Bachelor of Arts in Psychology from the California State University at Fullerton. She serves as an Advisory Board member of the Wharton Center for Human Resources Research Advisory Group of the University of Pennsylvania and as Vice Chairman of the Board of the Women’s Business Development Council.
Senior Vice President and General Manager, eClinicalRead Bio Read Bio
Jim Primerano oversees the delivery of the eClinical solutions portfolio. Jim has 20 years of clinical research and technology experience, leading teams to bring innovative solutions to the pharmaceutical industry in support of clinical development. Prior to joining, Jim was Sr. Director of Product Strategy with Medidata Solutions, where he was responsible for driving product portfolio expansion. Jim holds a Bachelor of Arts in Biology from the University of Pennsylvania and a Master of Business Administration in Global Business from Rider University.
Senior Vice President, Chief Medical OfficerRead Bio Read Bio
Dr. David Daniel provides overall scientific, clinical and strategic direction for our solutions. Dr. Daniel was the founder and President of Global Learning, LLC which was acquired by United BioSource Corporation in July 2006. He formerly served as Medical Director of the NIMH Neuroscience Center at Saint Elizabeth’s, Director of Clinical Trials for the Stanley Foundation and was a founding Principal of Best Practice, LLC. For over 30 years, Dr. Daniel has supervised and trained raters in psychiatric clinical trials globally. He has published numerous scientific articles involving clinical trials and investigations of the psychopathology of mental illness. He has received patent protection for new treatment approaches in epilepsy, anxiety disorders and psychotic disorders. Dr. Daniel graduated Phi Beta Kappa and Magna Cum Laude from Emory University and obtained his medical school and psychiatry post-graduate training at Vanderbilt University, where he served as chief resident. He was a medical staff fellow and senior staff fellow within the intramural program of the National Institute of Mental Health (DIRP, NIMH) for five years.
David G. Daniel, MD
Sr. Vice President and Chief Medical OfficerRead Bio Read Bio
Clinical Professor of Psychiatry, George Washington University
Dr. Daniel provides overall scientific, clinical and strategic direction for Signant Health’s services. Dr. Daniel was the founder and President of Global Learning, LLC which was acquired by United BioSource Corporation in July 2006. He formerly served as Medical Director of the NIMH Neuroscience Center at Saint Elizabeth’s, Director of Clinical Trials for the Stanley Foundation, and was a founding Principal of Best Practice, LLC. For over 20 years, Dr. Daniel has supervised and trained raters in psychiatric clinical trials in the US and globally. He has published numerous scientific articles involving clinical trials and investigations of the psychopathology of mental illness. He has received patent protection for new treatment approaches in epilepsy, anxiety disorders and psychotic disorders. Dr. Daniel graduated Phi Beta Kappa and Magna Cum Laude from Emory University and obtained his medical school and psychiatry post-graduate training at Vanderbilt University, where he served as chief resident. He was a medical staff fellow and senior staff fellow within the intramural program of the National Institute of Mental Health (DIRP, NIMH) for five years.
Steve Targum, MD
Scientific DirectorRead Bio Read Bio
Dr. Targum consults widely to the pharmaceutical industry regarding the design and implementation of clinical trials for new psychotropic drugs and the progression of drug development from concept to approval to launch. In addition to his work at Signant, Dr. Targum is a Chief Medical Advisor at Prana Biotechnology Ltd. and has served as Chief Medical Officer at several small biotechnology and pharmaceutical companies. In 1991, Dr. Targum established and operated a multi-site clinical trials program in Philadelphia. As Principal Investigator, he conducted over 200 clinical drug trials in therapeutic areas that included anxiety, depression, mania, schizophrenia, and Alzheimer’s disease. In 2001, Dr. Targum founded PharmaStar, a rater training and medical education company focused on CNS drug development and international clinical trials. The company grew quickly and became the global leader in this niche when it was sold in October 2004 to United BioSource Corporation. Previously, He was Professor of Psychiatry and Vice-Chairman of the Department of Mental Health Sciences at Hahnemann University School of Medicine (Philadelphia) from 1989-1995. He has published over 100 scientific articles in the areas of psychopharmacology, psychobiology, and clinical trials methodology. Dr. Targum has a B.A. in biology from Colgate University and an M.D. from Mount Sinai School of Medicine.
Joan Busner, Ph.D.
Clinical Vice PresidentRead Bio Read Bio
Dr. Busner has over 35 years of experience as an academic clinical psychiatric researcher. She has served as the Principal Investigator for 49 industry-sponsored psychiatric clinical trials and Sub-Investigator for 35 additional clinical trials. She has served continuously on University Institutional Review Boards (IRBs) for the 20 years that preceded her move to Signant Health. Dr. Busner is an active contributor to the psychopharmacology literature and has authored or co-authored over 140 peer-reviewed articles and national or international scientific presentations. Prior to Signant, Dr. Busner directed the psychiatric clinical trials units of two major medical schools. Dr. Busner has held medical school faculty appointments since 1985 and is currently Affiliate Associate Professor of Psychiatry at Virginia Commonwealth University. She serves as Signant’s Expert Presenter and Scientific Lead for US and multinational studies of pediatrics, rare and orphan diseases, depressive disorders, anxiety disorders, attention deficit hyperactivity disorder and all child and adolescent psychiatric indications. She has trained thousands of psychiatric clinical trial investigators across the globe and lectures frequently on the application of objective rating scales in the assessment of diagnosis and efficacy in psychopharmacology, ethics in psychiatric research, the placebo effect in psychiatric research and techniques for its minimization, the role of IRBs and clinical trial methodology. Dr. Busner received her PhD in Experimental Social Psychology and her MA in General Psychology from Adelphi University. She is licensed to practice psychology in Pennsylvania, Missouri and New York.
Gary Sachs, MD
Clinical Vice PresidentRead Bio Read Bio
Dr. Sachs is the Therapeutic Area Leader in bipolar disease and mood disorders at Signant. He previously co-founded Concordant Rater Systems, a specialty provider of technologies to improve CNS clinical research. Dr. Sachs is a recognized expert clinical trialist with extensive experience in rater training and the methodologies of mood and anxiety disorder research. He has been instrumental in developing technology-based solutions for randomized controlled trials that identify correlates of high placebo response, improve signal detection and reduce the risk of failed trials. Dr. Sachs is the founder and director of the Bipolar Clinic and Research Program at Massachusetts General Hospital (MGH) and is an Associate Professor of Psychiatry at Harvard Medical School. After graduating from the University of Pennsylvania and the University of Maryland Medical School, he completed his residency at MGH. His areas of academic interest include psychopharmacology, chronobiology, bipolar mood disorder and development of pragmatic measure-based practice guidelines. Dr. Sachs is Chair of the National Alliance on Mental Illness Scientific Advisory Board and serves on the Scientific Advisory Board of the Depression and Bipolar Support Alliance. He has authored over 200 articles, abstracts, books and book chapters.
David S. Miller, MD, MA
Clinical Vice PresidentRead Bio Read Bio
Dr. Miller has over 20 years of clinical, clinical research and teaching experience, primarily in the field of geriatric psychiatry. After completing his 2-year fellowship in geriatric psychiatry at the University of Pennsylvania, he joined the faculty and served as an Assistant Professor of Psychiatry. Dr. Miller then went on to the University of Medicine and Dentistry of New Jersey, where he served as an Associate Professor of Psychiatry. Prior to joining Bracket, Dr. Miller served as Chief of Geriatric Psychiatry, Medical Director of ECT, and President of the Medical Staff at Friends Hospital in Philadelphia, PA. At all of these institutions, he oversaw the education and training of medical students, residents and fellows in geriatric psychiatry, and was recognized with a departmental teaching award. Dr. Miller has served as a Principal Investigator in a number of dementia clinical trials. In addition, he has lectured locally, nationally and internationally on his dementia related research. Dr. Miller serves as the Co-Chair of the ISTAART funded Neuropsychiatric Syndromes in Dementia – Professional Interest Area (NPS-PIA), and as the Co-Chair of the ISCTM Working Group focusing on the same area. Additionally, Dr. Miller is a co-author on the updated ADCS ADAS-Cog administration and scoring manual. Since joining Bracket, Dr. Miller has consulted on multiple dementia protocols and has served as the Expert Presenter at dozens of investigators’ meetings across the globe, including those addressing behavioral abnormalities and agitation in the context of dementia.
Anthony T. Everhart, MD
Clinical Vice President, Internal MedicineRead Bio Read Bio
Todd Everhart, MD, FACP, is the internal medicine leader at Signant. Dr. Everhart is board-certified in internal medicine and a fellow of the American College of Physicians with over 23 years of experience in the practice of medicine and over 12 years of experience in clinical development. Prior to joining Signant, Dr. Everhart held positions of Vice President, Medical Affairs and Vice President, Medical Informatics at Chiltern and Covance, and consulted independently in the areas of medical monitoring, medical data review, data analytics, and physician adoption of technology. He has worked in all phases of clinical development in numerous therapeutic areas including allergy & immunology, cardiovascular, hematology & oncology, infectious disease & HIV, neurology, ophthalmology, psychiatry, respiratory, and rheumatology.
Lewis M. Fredane, MD
Clinical Vice PresidentRead Bio Read Bio
As Clinical Vice President, Dr. Fredane will serve as the Therapeutic Area Leader for neurology and will oversee Signant’s eCOA, Rater Training, and Quality Assurance work in this important therapeutic area. Prior to joining Bracket, Dr. Fredane served as a practicing neurologist and clinical assistant professor of Neurology at Drexel University College of Medicine in Philadelphia, Pennsylvania. He has worked in pharmaceutical drug development at several companies including at Sanofi/Genzyme Pharmaceuticals, Meda Pharmaceuticals and with CRO Omnicare Clinical Research. He also maintains extensive experience in medical affairs and has published research on multiple sclerosis, pain management and transplantation. Dr. Fredane received his medical degree from Albert Einstein College of Medicine and completed his training with a residency in Neurology at Duke University. He completed fellowships in Clinical Immunology at St. Luke’s-Roosevelt Hospital Center in New York and in Immunology at Yale University School of Medicine in New Haven, Connecticut through a research fellowship with the National MS Society.
Scott Hamilton, Ph.D.
Principal BiostatisticianRead Bio Read Bio
Adjunct Professor, Stanford University School of Medicine, Dept. of Neurology and Neurological Sciences
Dr. Hamilton was President and Founder of DynaRand, LLC, a software company that pioneered the development of IVRS and IWRS solutions for clinical trials management. DynaRand was acquired by United BioSource Corporation in 2005. Since the inception of DynaRand in 1998, he has pioneered the use of IVRS for automated adaptive studies, especially in the area of dynamic randomization. Dr. Hamilton works closely with pharmaceutical companies regarding the statistical aspects of adaptive trials and randomization algorithms, in addition to monitoring the integrity of Signant’s randomization processes. Previously, Dr. Hamilton held a role of Senior Biostatistician at Genentech, Inc. and is a NI-NINDS Grant Review Committee member. Widely published, he holds memberships in the American Statistical Association and the American Academy of Neurology and Biometrics. Dr. Hamilton received his undergraduate degree from the University of California at Davis in Economics and Rhetoric, his Master of Science from the University of California at Los Angeles in Biostatistics, and his PhD in Biostatistics from the University of North Carolina.
Alan Kott, MUDr.
Clinical Vice President and Practice Lead, Data AnalyticsRead Bio Read Bio
Dr. Kott is based in Signant’s Prague office and until recently was Senior Clinical Manager for Europe. Having led the development of the Data Analytics Program for Bracket, he has overseen the design and reporting of data analytics in multiple large schizophrenia studies. For the past seven years, he has also provided training to investigators as an Expert Trainer. Dr. Kott has been responsible for the design and implementation of multiple in-study data quality programs and served as a Product Business Owner for Rater Reliability Statistical Measures Application. Prior to Bracket, Dr. Kott worked as a house officer in Psychiatry at General Teaching Hospital, Department of Psychiatry, and as an Assistant Professor at Charles University, 1st Medical Faculty – Department of Psychiatry, in Prague. Dr. Kott has a Medicinae Universae Doctor (MUDr.) from Charles University.
Bill Byrom, Ph.D.
VP Product Intelligence and PositioningRead Bio Read Bio
Bill serves as Vice President of product intelligence and positioning at Signant Health, where he also serves as a principal ePRO scientist. He has worked in the Pharmaceutical industry for 30 years and is the author of over 70 publications and two industry textbooks on electronic patient-reported outcomes (ePRO). His recent scientific work includes the use of wearable technology and bring- your-own-device (BYOD) eCOA in clinical trials. Bill recently served as Vice Director of the C-PATH ePRO Consortium, and is an active member of the DIA Study Endpoints Community where he leads a cross-disciplinary group on the use of endpoints derived from wearable devices to support labelling claims and regulatory decision making. Bill provides independent eClinical commentary via LinkedIn and Twitter (@billbyrom).